Laser Treatment for Glioblastoma Shows Survival Benefit

Key Points

• A multicenter analysis of 787 brain tumor patients evaluated outcomes after laser interstitial thermal therapy (LITT).
• For newly diagnosed glioblastoma, destroying at least 91% of the tumor was associated with survival of 2.1 years from diagnosis.
• Earlier LITT for small brain metastases after radiation was associated with better survival outcomes.
• The minimally invasive procedure was linked to rapid recovery, short hospital stays, and preserved quality of life.
• For More Updates in Neurology, register for American Neurology Summit 2026 (ANS2026)

How Does Laser Treatment for Glioblastoma Work?

Laser treatment for glioblastoma is gaining attention as a minimally invasive option for selected patients with recurrent, difficult-to-access, or otherwise inoperable brain tumors. The approach, known as laser interstitial thermal therapy (LITT), uses a small opening in the skull to insert a laser probe into the tumor.

Using real-time MRI guidance, neurosurgeons can direct the probe through the brain while limiting injury to surrounding healthy tissue. The laser then generates controlled heat to destroy tumor cells. Unlike conventional open brain surgery, LITT requires only a small incision and can allow patients to return home sooner.

A new analysis led by Washington University School of Medicine in St. Louis evaluated 787 patients treated across 25 U.S. centers. Published in the Journal of Clinical Oncology, the study examined factors associated with improved outcomes following laser therapy.

Can Laser Treatment Extend Survival in Glioblastoma?

The researchers found that the extent of tumor destruction played an important role in survival, particularly among patients with newly diagnosed glioblastoma. Patients who achieved at least 91% tumor clearance had a survival of 2.1 years from diagnosis.

This finding is clinically relevant because conventional open surgical resection for glioblastoma is associated with a median survival of approximately 1.5 years. The results suggest that LITT may warrant consideration earlier in treatment for carefully selected patients, although further clinical evaluation is needed to define its appropriate role.

The study also identified a potential timing factor in brain metastasis treatment. Patients whose metastatic tumors were still small when treated with LITT experienced better survival outcomes than those treated after further tumor growth. These findings may prompt clinicians to reconsider prolonged imaging-based observation in selected patients after prior radiation therapy.

What Are the Quality-of-Life Benefits of LITT?

Beyond survival, the analysis reinforced the tolerability of laser interstitial thermal therapy for brain tumors. Patients typically required a hospital stay of about 32 hours, with many avoiding intensive care and readmission. The minimally invasive approach also supported faster recovery and reduced reliance on anti-seizure medication compared with pretreatment levels.

For More Updates in Neurology, register for American Neurology Summit 2026 (ANS2026)

For neurosurgeons, neuro-oncologists, radiation oncologists, and oncology nurses, these findings highlight tumor volume, treatment timing, and extent of ablation as important considerations when evaluating LITT candidates. The results support continued investigation of this technology as part of multidisciplinary brain tumor care.

Source:

WashU Medicine